Services Sector Ideas

[gfp927z]

Motorola Solutions (MSI) - ascending triangle

[gfp927z]

Church + Dwight (CHD) - ascending triangle -

[gfp927z]

BCE Inc (BCE) - ascending triangle -

[gfp927z]

Euro (FXE) - bearish descending triangle, lower support didn't hold, and chart also broke below the Oct low. Next support looks like 128 area -


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70028267

[gfp927z]

>>> Alimera, pSivida Strike Out On Eye Implant Drug


by: EP Vantage
November 15, 2011



http://seekingalpha.com/article/307897-alimera-psivida-strike-out-on-eye-implant-drug?source=yahoo




Two strikes may be enough to knock Iluvien out of its regulatory ball game. On Friday came news of a second complete response letter from the FDA for the eye implant drug to treat diabetic macular edema (DME), sending the shares of its developers, Alimera Sciences (ALIM) and pSivida (PSDV), tumbling to record lows.

Fundamental to the disappointment is the FDA’s request for not one but two additional clinical trials to prove Iluvien is safe and effective in DME – essentially sending the drug back to the drawing board. Alimera, shares in which were hammered 73% down to $1.96, is maintaining its commitment to the drug for now, not least because approval in Europe could still be forthcoming with the UK’s MHRA due to make a recommendation by the end of the year. Whether the company attempts a third strike in the US will depend on the outcome of a review meeting next month with the FDA.

All in

Regulatory progress with Iluvien is critical to the prospects of both companies (Event - Alimera and pSivida hope Iluvien will be second time lucky, October 10, 2011).

Alimera developed Iluvien – a tiny injectable implant to the eye that slowly emits a very low dose of the corticosteroid fluocinolone acetonide – with technology licensed from pSivida, the Australian biotech hoping to receive a $25m milestone for FDA approval and a 20% profit on global sales. pSivida’s Nasdaq listed stock fell 49% to $2.02 on Friday.

Both companies are now valued not much above current cash levels. Alimera held $39m in cash as of the end of September and is now worth $62m; pSivida’s new market capitalisation of $38m compares to a cash reserve of $21m.

On a conference call with investors Monday Alimera provided little insight into the nature of the additional clinical trials required, preferring instead to talk up the chances of gaining approval in Europe and securing a commercial partner for this region. The company has also suspended recruitment and treatment in an ongoing 100-patient trial of Iluvien using a new inserter device; around 60 patients have been recruited so far.

Assuming the pivotal trial, dubbed Fame, was well designed and conducted, it is hard to see Iluvien performing any better in two further clinical studies, in terms of providing the required efficacy and safety data to soothe the FDA’s concerns.

EU reprieve?

Hence the keenness to talk about Illuvien’s chances in Europe. The product was filed under the de-centralised procedure, with the UK as the reference member state. The UK’s regulatory body MHRA is expected to make a recommendation shortly on Iluvien’s approvability to the so-called ‘concerned member states’ of Austria, France, Germany, Italy, Portugal and Spain; a final decision is expected in the first half of 2012.

Alimera believes the market opportunity in Europe is similar in size to the US, where analysts had pencilled in sales of $400m by 2016, and is encouraged by the more proactive regulatory process in Europe – sponsors of new products tend to have more opportunity to be made aware of and then time to address any concerns the authorities may have.

As such, the company remains bullish about its chances of gaining approval in Europe and securing a commercial partner; negotiations are said to be ongoing.

As to Iluvien’s American future, the follow up meeting with the FDA will be critical in determining whether Alimera presses on with the drug for DME. Although phase II trials are ongoing in age-related macular degeneration and retinal vein occlusion, the FDA’s feedback, particularly the extent of its concerns over the adverse reactions linked to the drug, may yet put a brake on all further development.

Alimera’s cash reserve is clearly sufficient to cover immediate needs, including completing the European regulatory process, but embarking on further trials of Iluvien may stretch investor confidence and support beyond breaking point. Announcement of an often infamous ‘strategic review’ may not be far away.

<<<

[gfp927z]

Alimera Sciences (ALIM) -



>>> These 2 Biotechs Got Crushed



By David Williamson
November 12, 2011


http://www.fool.com/investing/high-growth/2011/11/12/these-2-biotechs-got-crushed.aspx



On a day when the Dow Jones Industrial Average (INDEX: ^DJI ) surged 260 points as the European debt drama continues to unfold, significantly larger moves happened in the health-care sector. Friday's big headline: A pair of biotech companies got crushed after receiving a complete response letter (CRL) from the FDA.

The biggest mover was Alimera Sciences (Nasdaq: ALIM ) . Shares collapsed 73% as the company's flagship drug candidate, Iluvien, was rejected by the FDA. pSivida (Nasdaq: PSDV ) , which licensed the technology to Alimera, lost nearly 50% of its value.

This is the second CRL Iluvien has received, although analysts had expected a better result on its second go-around. The FDA isn't convinced that the benefits of the treatment for diabetic macular edema outweigh the risks and is requiring two additional trials. Alimera doesn't have the money to run those tests, which would probably result in additional debt, dilution, or both. A buyout could be possible, but it's a stretch to think other drugmakers are licking their chops over a twice-rejected treatment. So investors shouldn't count on Pfizer (NYSE: PFE ) , which is working with pSivida on its own eye implant, to ride in on a white horse.

Alimera's next move is to…


<<<

[gfp927z]

Targacept earnings - Nov 1, 2011 -



>>> Targacept Reports Third Quarter 2011 Financial Results


Winston-Salem, North Carolina
November 01, 2011


http://www.targacept.com/wt/page/pr_1320176416




Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2011.

Targacept reported net loss of $9.1 million for the third quarter of 2011, compared to net income of $2.5 million for the corresponding 2010 period, and net income of $1.3 million for the nine months ended September 30, 2011, compared to net income of $13.1 million for the corresponding 2010 period. As of September 30, 2011, cash and investments in marketable securities totaled $270.9 million.

"We look forward to top-line results becoming available soon from the first of five studies in the Phase 3 RENAISSANCE Program for TC-5214, a drug candidate under investigation as an adjunct to antidepressant treatment for patients with major depressive disorder who do not respond adequately to initial therapy," said J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept. "Our recent initiation of the Phase 2b trial of AZD3480 in Alzheimer's disease reflects our commitment to advancing a deep pipeline of innovative NNR Therapeutics, with the goal of delivering new medicines to build health and restore independence for patients in multiple areas where large unmet medical needs continue to exist."

Recent Highlights and Program Updates:


TC-5214 (co-development with AstraZeneca)

Enrollment completed in each of the five clinical trials - two fixed dose studies, two flexible dose studies and one long-term safety study - that comprise the Phase 3 RENAISSANCE Program designed to support a planned second half of 2012 filing of a new drug application with the FDA as an adjunct to antidepressant therapy for major depressive disorder (MDD);
Expect to report top-line results this month from a flexible dose clinical trial conducted in Europe (RENAISSANCE 3), the first study in the RENAISSANCE Program to complete; results from the remaining RENAISSANCE Program studies expected to be reported through the first half of 2012;
Recruitment continuing for a Phase 2b "switch" monotherapy trial, known as the EXPLORER study, for patients with MDD who do not respond adequately to initial treatment with an SSRI or SNRI;


TC-5619

Planned Phase 2b clinical trial for further evaluation as a treatment for negative symptoms and cognitive dysfunction in schizophrenia expected to initiate by the end of 2011 or in early 2012;
Further analysis of the full dataset from the completed Phase 2 ADHD clinical trial revealed encouraging efficacy signals on the Conners' Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms score (the primary outcome variable) in patients with inattentive predominant ADHD; expect to initiate a Phase 2 study to further assess potential of this product candidate to benefit these patients by the end of 2011 or in early 2012;
Completed enabling activities for a potential Phase 2 clinical trial of TC-5619 in Alzheimer's disease; evaluation of additional Alzheimer's disease development remains ongoing;


AZD3480 and AZD1446

Initiated a Phase 2b potential registration study of AZD3480 in mild to moderate Alzheimer's disease and received $2.0 million in payments from AstraZeneca in the third quarter;
Based on feedback received from AstraZeneca, further development of AZD3480 in ADHD is not currently expected and AstraZeneca's decision surrounding any future development of AZD1446 in Alzheimer's disease is anticipated by the end of the year;


TC-6987

Executed contingency plans to address slower than expected enrollment in ongoing Phase 2 clinical studies in asthma and type 2 diabetes; expect to complete both studies in the first half of 2012;

Scientific Leadership

Remained at the forefront of NNR research, with the following publications authored or co-authored by Targacept scientists:
Kucinski AJ, Stachowiak MK, Wersinger SR, Lippiello PM, Bencherif M. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr Pharm Biotechnol 12: 437-48 (2011);
Lippiello PM, Mazurov A, Bencherif M. The ?7 nicotinic acetylcholine receptor in health and disease. In Pharmacology of Nicotinic Acetylcholine Receptors from the Basic and Therapeutic Perspectives, Ed. Hugo R. Arias. pp. 101-150 (2011); and
Letchworth, SR, Whiteaker, P. Progress and challenges in the study of ?6-containing nicotinic acetylcholine receptors. Biochem Pharmacol 82: 862-72 (2011);
Contributing to the burgeoning field of NNR research with planned participation at "Nicotinic Acetylcholine Receptor-Based Therapeutics: Emerging Frontiers in Basic Research & Clinical Science," a satellite meeting to the Society for Neuroscience taking place in Washington, D.C. on November 9-11, 2011; and
Company Developments

Named by Deloitte for 2011 to its Technology Fast 500(TM), a ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America; recognition based on Targacept's revenue growth of 211% from 2006 to 2010.
Financial Results

Targacept reported net loss of $9.1 million for the third quarter of 2011, compared to net income of $2.5 million for the third quarter of 2010. The net loss position for the 2011 period as compared to net income for the 2010 period was primarily due to an increase in research and development expenses and a decrease in amounts recognized into revenue from payments previously received from AstraZeneca and GlaxoSmithKline. For the nine months ended September 30, 2011, Targacept reported net income of $1.3 million, compared to net income of $13.1 million for the corresponding period of 2010. The decrease in net income for the 2011 period was primarily due to an increase in research and development expenses, partially offset by an increase in amounts recognized into revenue from payments previously received from AstraZeneca and GlaxoSmithKline. Non-cash, stock-based compensation charges of $2.1 million and $1.2 million were recorded for the third quarter of 2011 and 2010, respectively, and $6.5 million and $3.7 million for the nine months ended September 30, 2011 and 2010, respectively.

Net operating revenues totaled $19.0 million for the third quarter of 2011, compared to $21.8 million for the third quarter of 2010. The lower net operating revenues for the 2011 period were principally attributable to decreases of $2.4 million in recognition of deferred revenues associated with TC-5619 and $826,000 in recognition of deferred revenues associated with a now concluded alliance with GlaxoSmithKline.

For the nine months ended September 30, 2011, net operating revenues totaled $78.7 million, compared to $62.2 million for the corresponding 2010 period. The higher net operating revenues for the 2011 period were principally attributable to increases of $15.9 million in recognition of deferred revenues associated with the concluded GlaxoSmithKline alliance and $638,000 in recognition of deferred revenues associated with TC-5619.

Research and development expenses totaled $25.4 million for the third quarter of 2011, compared to $17.3 million for the third quarter of 2010. The higher research and development expenses were principally attributable to increases of $7.4 million in costs incurred for third-party research and development services in connection with clinical-stage product candidates, $1.4 million in costs incurred for third-party research and development services in connection with preclinical programs and $793,000 in other research and development-related operating costs, including compensation-related expenses for research and development personnel and infrastructure costs. These increases were partially offset by the inclusion for the 2010 period of a $1.5 million upfront payment made to Cornerstone Therapeutics Inc. in August 2010. The higher costs incurred for third-party research and development services in connection with clinical-stage product candidates for the 2011 period were principally due to: a greater level of development activities for TC-5214 as the Phase 3 program progressed; the conduct of activities in preparation for a Phase 2b clinical trial of AZD3480 in Alzheimer's disease; and the conduct of two Phase 2 clinical trials of TC-6987; partially offset by lower clinical trial costs for TC-5619 as a result of the completion of two Phase 2 studies.

For the nine months ended September 30, 2011, research and development expenses totaled $69.1 million, compared to $42.1 million for the corresponding 2010 period. The higher research and development expenses were principally attributable to increases of $22.0 million in costs incurred for third-party research and development services in connection with clinical-stage product candidates, $3.6 million in costs incurred for third-party research and development services in connection with preclinical programs and $3.0 million in other research and development-related operating costs, including compensation-related expenses for research and development personnel and infrastructure costs. These increases were partially offset by the inclusion for the 2010 period of the upfront payment to Cornerstone Therapeutics Inc. The higher costs incurred for third-party research and development services in connection with clinical-stage product candidates for the 2011 period were principally due to the activities described above for the third quarter, further offset by a decrease in costs for TC-6499 as a result of the completion of an exploratory Phase 2 clinical study in the third quarter of 2010.

General and administrative expenses totaled $2.8 million for the third quarter of 2011, compared to $2.1 million for the third quarter of 2010. The higher general and administrative expenses were primarily attributable to an increase of $718,000 in compensation-related expenses for general and administrative personnel. For the nine months ended September 30, 2011, general and administrative expenses totaled $9.1 million, compared to $5.7 million for the corresponding 2010 period. The higher general and administrative expenses were principally attributable to increases of $2.2 million in compensation-related expenses for general and administrative personnel and $1.3 million in infrastructure costs associated with growth.

There was no income tax expense for the third quarter or nine months ended September 30, 2011, compared to income tax expense of $257,000 and $2.4 million for the third quarter and nine months ended September 30, 2010, respectively. Income tax expense for the 2010 periods was primarily due to the income tax effect of stock option exercises that is recognized only in certain circumstances.

Updated Financial Guidance

Targacept now expects its cash, cash equivalents and investments balance to be at least $240 million at December 31, 2011. Targacept continues to expect its cash resources to be sufficient to meet its operating requirements at least through the end of 2014. This guidance does not include amounts that Targacept could receive if any milestone events are achieved under its collaboration agreements with AstraZeneca. Targacept is not making any adjustment to its previously announced guidance for expected net operating revenues or expected operating expenses for the year ended December 31, 2011.

Conference Call

As previously announced, Targacept will be hosting a conference call and webcast today, November 1, 2011, at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing [phone] for domestic participants and [phone] for international callers (reference passcode 91779970). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Time on November 1, 2011 through November 15, 2011 by dialing [phone] for domestic callers and [phone] for international callers (reference passcode 49874736).

A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

Forward-Looking Statements

This press release includes "forward-looking statements" made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, without limitation: the progress or scope of development of TC-5214, TC-5619, AZD3480, AZD1446, TC-6987 or any other Targacept product candidate or program, such as the target indication(s) for development, the size, design, population, conduct, duration or objective of any clinical trial or the timing for initiation or completion of or reporting of results from any clinical trial or for submission or approval of any regulatory filing (such as a new drug application with the FDA); the timing for a decision by AstraZeneca whether to conduct further development of AZD1446 in Alzheimer's disease; any further development of AZD3480 in ADHD; the competitive position of any Targacept product candidate or the commercial opportunity in any target indication; any payments that AstraZeneca may make to Targacept; or Targacept's plans, expectations or future operations, financial position, revenues, costs or expenses. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation Targacept's critical accounting policies and risks and uncertainties relating to: Targacept's dependence on the success of its collaborations with AstraZeneca; the control or significant influence that AstraZeneca has over the development of TC-5214, AZD3480 and AZD1446, including as to the timing, scope and design of any future clinical trials and as to the conduct at all of further development of AZD1446 in Alzheimer's disease; the conduct and results of clinical trials and non-clinical studies and assessments of TC-5214, TC-5619, AZD3480, AZD1446, TC-6987 and any other Targacept product candidate, including the performance of third parties engaged to execute such trials, studies and assessments, delays resulting from any changes to the applicable protocols and difficulties or delays in the completion of subject enrollment or data analysis; whether positive findings from completed clinical trials of TC-5214 or TC-5619 will be replicated in ongoing or any future clinical trials of that product candidate; Targacept's ability to protect its intellectual property; and the timing and success of submission, acceptance and approval of regulatory filings. These and other risks and uncertainties are described in greater detail under the heading "Risk Factors" in Targacept's most recent Annual Report on Form 10-K and in other filings that it makes with the Securities and Exchange Commission. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Targacept cautions you not to place undue reliance on any forward-looking statement.

In addition, any forward-looking statement in this press release represents Targacept's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Targacept disclaims any obligation to update any forward-looking statement, except as required by applicable law.

NNR Therapeutics™, Pentad™ and Building Health, Restoring IndependenceSM are trademarks or service marks of Targacept, Inc. Any other service marks, trademarks and trade names appearing in this press release are the properties of their respective owners.

TARGACEPT, INC
Unaudited Condensed Statements of Operations
(in thousands, except share and per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2011 2010 2011 2010

Net operating revenues $ 18,955 $ 21,798 $ 78,692 $ 62,218

Operating expenses:
Research and development 25,444 17,329 69,146 42,058
General and administrative 2,842 2,052 9,146 5,688

Total operating expenses 28,286 19,381 78,292 47,746

Operating (loss) income (9,331 ) 2,417 400 14,472
Interest income, net of interest expense 277 326 876 986

(Loss) income before income taxes (9,054 ) 2,743 1,276 15,458
Income tax (expense) benefit - (257 ) - (2,395 )

Net (loss) income $ (9,054 ) $ 2,486 $ 1,276 $ 13,063

Basic net (loss) income per share $ (0.27 ) $ 0.09 $ 0.04 $ 0.46

Diluted net (loss) income per share $ (0.27 ) $ 0.08 $ 0.04 $ 0.43

Weighted average common shares
outstanding - basic 33,377,874 28,622,187 31,049,104 28,482,224

Weighted average common shares
outstanding - diluted 33,377,874 30,173,406 32,361,508 30,109,023
TARGACEPT, INC
Unaudited Condensed Balance Sheets
(in thousands)
September 30, December 31,
2011 2010
Cash, cash equivalents and investments $ 270,860 $ 252,509
Collaboration receivables and other current assets 3,334 4,057
Property and equipment, net 5,409 6,072
Other assets, net 136 149
Total assets $ 279,739 $ 262,787

Current portion of deferred revenue $ 74,449 $ 81,710
Other current liabilities 19,132 16,947
Deferred revenue, net of current portion 1,951 70,934
Long-term debt, net of current portion 2,195 1,349
Total stockholders' equity 182,012 91,847
Total liabilities and stockholders' equity $ 279,739 $ 262,787

Contacts

<<<

[gfp927z]

Targacept - charts -

[gfp927z]

Targacept - MF article, Nov 18, 2011 -



>>> Our Top Biotech Stock Idea



By CAPS' Weekly Top Stock Idea
November 18, 2011


http://www.fool.com/investing/high-growth/2011/11/18/our-top-biotech-stock-idea.aspx



This Week's Pitch:

Disclaimer: Yesterday I took a major CAPS kick to the teeth when the company reported that the RENAISSANCE 3 phase III trial of TC-5214 for major depression did not meet its primary endpoint. Not only did I green thumb Targacept, but I identified it in May as a GBMB portfolio buy at 20 after it had declined from peaks near 30 over a few months. Fortunately, my skepticism over the current paradoxical strength in the broad markets caused me to place a virtual moratorium on long investments until the debt crisis in Europe has resolved. Therefore I sustained no real money losses when the share price went into the dumper.

I've long held the view that when you advise buying a stock and you end up being completely wrong, you should sit down and shut up. This is apparently a rare concept in the financial media and on blog sites like Seeking Alpha. However, CAPS is a game and I'm going to continue to play Targacept in the game, and when I rate stocks I always write a pitch. So if you believe, like I do, in the integrity of fading away quietly then read no further.

Targacept conveniently dished the bad news only a week after reporting their third quarter financial results. So we know that the company has 271M in cash, 2M in long term debt, and an uptick in quarterly burn to 9M. Meanwhile, the market cap at the close Tuesday was 254M. Yes, that's 15M below the net liquid asset balance. Now, it's not unusual for weak biotechs to be valued below cash-see Insmed and Adventrx-but there are important differences with respect to Targacept.

First is the sheer quantity of the cash. Insmed has 85M to back a market cap of 80M. Adventrx has 38M to back a market cap of 26M. Targacept has a whopping 271M in cash. Even if they maintain the higher 9M burn they have enough cash for seven and a half years of operations. TC-5214 may have brought a lot of pain today, but let's not forget it brought in 200M from Astra Zeneca [ (NYSE: AZN ) ] in January 2010 and powered an 80M dilutive financing in May 2011.

The second issue is future prospects. Adventrx has two busted me-too cancer drugs and a cheaply acquired moonshot for sickle cell. Insmed has a phase III antibiotic on FDA clinical hold for a cancer signal in animal studies. Investors could be forgiven for thinking that these companies will simply use up their cash fruitlessly a la Myrexis. Targacept, on the other hand, has four drugs besides TC-5214 in advanced clinical trials. The most promising of these, AZD3480, is already in a phase IIb trial in Alzheimer's being run by Astra Zeneca. Phase II trials of TC-6987 in asthma and diabetes will be completed in H1 2012. And furthermore, it's important to remember that RENAISSANCE 3 was only one of four phase III efficacy trials of TC-5214 in progress. The remaining trials will provide topline data in H1 2012.

I think it would be foolhardy to ascribe much value to TC-5214, and the stock could suffer further if Astra Zeneca declines to pick up an option on AZD1446 for Alzheimer's later this year. But I've looked at this situation closely and everything about it is saying over-reaction. For some reason it reminds me of the pummeling Intermune took after the FDA rejected pirfenidone in May 2010. We know how that story turned out. Anyone could be excused for giving speculative stocks like baby pharmas a wide berth given the current imbalance between the markets and the real global economic situation. But if you're looking for something in the sector that has a good chance of bouncing back regardless of the economic headwinds, Targacept may be for you

<<<

[gfp927z]

New Jersey Resources -

[gfp927z]

Church + Dwight -

[gfp927z]

Bottom Plays 2 - updated -


Diamond Foods -








Idenix -









MedQuist Holdings -








Micronetics -








Pacific Ethanol -









Pacific Sunwear -








Plug Power -








Toreador Resources -








Velti -

[gfp927z]

Bottom Plays 1 - updated -


Alliance Healthcare -








American Superconductor -








American Electric Technologies -








Analysts International -








CalAmp -








Cyanotech -








Gold Reserve -








ID Systems -

[gfp927z]

Bottom plays to watch -


Alliance Healthcare -




American Superconductor -




Analysts Intl -




CalAmp -




Cyanotech -




ID Systems -




Pacific Sunwear -




Plug Power -




Toreador Resources -




Velti -

[gfp927z]

Broadcom (BRCM) - possible short candidate? It has fallen thru key support. This stock was mentioned in a Nov 10 Stockpickr article as an 'if/then' trade -


http://stockpickr.com/5-breakout-stocks-recoup-your-losses.html


Chart on Nov 10 -





Chart now, Nov 25 -

[gfp927z]

Toreador Resources (TRGL) - interesting chart. They're a small oil + gas outfit in France, only $88 mil market cap -


http://stockpickr.com/5-stocks-setting-break-out.html-13










>>> Another stock that’s setting up for a big breakout is Toreador Resources (TRGL), an independent energy company engaged in the exploration and production of crude oil with interests in developed and undeveloped oil properties in the Paris Basin, France. The sellers have destroyed this stock in 2011, with shares off by over 75%.

If you take a look at the chart for Toreador Resources, you’ll see that this stock was beaten down from its July high of $4.31 a share to a recent low of $2.62. Since printing that low, this stock has been uptrending strong and making mostly higher lows and higher highs. Now the stock is trading within range of a big breakout if it can manage to move above two key overhead resistance levels.

Traders should watch for a sustained move and close above $4.19 to $4.31 a share on high volume to trigger a breakout trade. Look for volume that’s tracking in close to or above its three-month average action of 139,111 shares. If we get that high-volume breakout, then look for this stock to make a monster spike back towards its 200-day moving average of $5.98.

You could be a buyer of this stock off any weakness back toward the 50-day moving average of $3.24. I would use a mental stop just below that level if you buy off weakness. You could also buy off strength and get long once $4.19 to $4.31 are taken out with volume to the upside. Simply use a mental stop a few percentage points below $4.19 if you buy off strength.

I also included Toreador in a recent list of Stocks Under $10 Setting Up to Trade Higher. <<<

[gfp927z]

>>> Royale Energy Set To Post Large Gains In Coming Days (Along With 7 Other Energy Stocks)


by: Brian Nichols
November 23, 2011


http://seekingalpha.com/article/309774-royale-energy-set-to-post-large-gains-in-coming-days-along-with-7-other-energy-stocks?source=yahoo




In late February there were a dozen small cap, and large cap, energy stocks that posted very large gains in a matter of days. The gains were caused by an increase in the price of crude and optimism surrounding natural gas. Yet of all the energy stocks that posted gains, Royale Energy's (ROYL) gains were among the largest, as it increased by nearly 400% in just ten trading days. The stock has since regressed and is now trading at $3.29, after a 12.67% gain on Tuesday, yet I believe it's now perfectly positioned to repeat history and post large gains once again.

Royale Energy, Inc. is an independent oil and natural gas producer. Yet most of the company's recent developments have surrounded its natural gas production and its Goddard wells. On Tuesday, news was released that the company had made two additional natural gas discoveries in its core areas. The deepest zone has been completed with a stabilized production rate of three million cubic ft. of natural gas per day. The Goddard wells have produced a total of 2 billion cubic ft. of natural gas which is high production and shows progress for the company.

This news reminded me very much of February when the Goddard began drilling and the news that another well would begin drilling in the near future. From the minute the company announced that the Goddard wells were drilling there was an immediate reaction of optimism among investors, and I believe most would agree the progress of the wells have been a pleasant surprise. The company's gains in February were a result of several factors including: drilling progress, stabilized natural gas prices, and large gains in crude oil.

The reason that I believe Royale Energy could very well be looking at similar gains over the next few weeks is because the events that took place in February are similar today. And although there are many differences, I believe the conditions for Royale to post gains are similar enough to result in some level of gains. Most of the optimism surrounding this company is driven by its natural gas, yet natural gas has steadily declined since July of 2008.

However, in February the commodity stabilized and over the last five trading days the commodity has shown some stabilization, which comes at a good time considering ROYL plans to begin selling its gas in the next two weeks. This development was made public with the announcement of the new found discovery of natural gas, which led to a 12.67% gain on Tuesday.

I believe there were three catalysts that caused the stock to triple in February: stabilizing natural gas prices, encouraging news on its wells, and rising crude price. I have already discussed the recent encouraging news regarding new found natural gas and the stabilization of nat gas over the last five trading days. Therefore, it only leaves rising crude, and if you've watched the market since October 1, you would know that crude has been consistently rising. But what's even more interesting is the price of crude when ROYL began rising in February, which was $97.44, near its current price. Back in February crude had been on an uptrend from $78.73, which took place over a period of several months. And then, once crude reached $98 and nat gas stabilized several small, medium, and large energy companies began to rise by large margins.

In February, when ROYL increased by more than 300%, the NASDAQ had lost 85 points during the same period. I believe that investors were looking for a place to make money as the markets were falling and found large gains in energy stocks. During that time everything fell into place and caused small-cap stocks to rise. There was pessimism in the market, rising oil prices, stabilized nat gas prices, and as a company ROYL had announced encouraging news which caused its stock to increase more than most.

The same events are playing out in today's market, and although the gains may not be as large, I still believe gains could be significant. Royale is a company with investor confidence and is trading with a market cap of only $35.41 million with $10.76 million shares, therefore, the stock can be easily manipulated. And since volume has already begun to increase, more than double on Tuesday, I believe it's very possible that these gains could come sooner rather than later.

In February, there were several energy stocks that posted large gains. I believe that ROYL is the fundamentally strongest of the small-cap stocks and has a high level of optimism surrounding its future and presents a likely chance to post gains over the next few weeks. However, if February were to repeat itself, there will be other stocks to rise. Therefore, I have included a few additional stocks, both small and large, and the dates and gains that each stock posted during that time.

I will finish by saying there were hundreds of little factors that played into the energy sector's reaction in February, I have only listed a few large factors. And anyone who follows the market for a long period of time knows that the market is ever changing and results are never the same, however, history does repeat itself on occasions. And while I doubt the gains will be as large, because of the high negativity surrounding the market, I do believe that some gains are likely and that energy stocks, such as ROYL and the ones listed below, may return some gains to investors that are desperately seeking a profit in this market with factors that are nearly identical to February.


Company Ticker Date Price Date Price
Crude Oil 02/16 $97.16 03/07 $108.88
Nat Gas 02/16 $4.65 03/07 $4.66
Royale Energy (ROYL) 02/22 $2.10 03/02 $7.90
Lucas Energy (LEI) 03/01 $2.09 03/07 $4.95
Chesapeake Energy (CHK) 02/18 $30.43 02/28 $35.95
SandRidge Energy (SD) 02/22 $8.61 03/07 $11.26
Samson Oil & Gas (SSN) 02/17 $2.73 03/07 $4.53
Blue Dolphin Energy (BDCO) 02/17 $2.49 03/04 $8.42
Triangle Petroleum (TPLM) 02/22 $7.30 03/04 $9.16
Delta Petroleum (DPTR) 02/22 $7.25 03/01 $13.30


Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in ROYL, SD over the next 72 hours. <<<

[gfp927z]

>>> Royale Continues to Turn Prospects Into Production


Press Release: Royale Energy
Tue, Nov 22, 2011 7:40 AM EST



• Royale Jewel Tests 3,000,000 Cubic Ft. Per Day

• Royale Bristol Finds 40 Ft. of Log Pay With 2,200 PSI Shut-In Pressure



http://finance.yahoo.com/news/Royale-Continues-Turn-pz-816003236.html?x=0&l=1


SAN DIEGO, Nov. 22, 2011 (GLOBE NEWSWIRE) -- Royale Energy, Inc. (Nasdaq:ROYL - News) has made two more natural gas discoveries in its core area. The Royale Jewel has been drilled to its total depth. The well is in close proximity to Royale's production facilities and will begin selling gas in two weeks. Three separate Forbes sands were encountered and the deepest zone has been completed with a stabilized production rate of 3,000,000 cubic ft. of natural gas per day. Last year the company began producing its Goddard wells 3/4's of a mile to the north. The Goddard wells have already produced over 2 billion cubic ft. of natural gas to date.

The Royale Bristol was drilled to a total depth of 6,800 ft. and found 40 ft. of Forbes filled natural gas sands. Production casing has been set and the well has a bottom hole shut in pressure of 2,200 psi.

The company has also continued its workover program by recompleting another existing well. The Parks well is now producing from a shallower zone at a stabilized rate of 190,000 cubic ft. per day.

These new discoveries are a confirmation of the significance of Royale's recently approved new 3D seismic survey. The company will be shooting a 25 square mile 3D seismic survey to expand its prospect and production area to the northwest. They are also a very positive step in the company's continuing success of replacing and growing its natural gas reserves.

About the Company

Headquartered in San Diego, Royale Energy, Inc. is an independent energy company. The company is focused on development, acquisition, exploration, and production of natural gas and oil in California, Texas and the Rocky Mountains. It has been a leading independent producer of oil and natural gas for over 20 years. The company's strength is continually reaffirmed by investors who participate in funding over 50% of the company's new projects. Additional information about Royale Energy, Inc. is available on its web site at www.royl.com. <<<

[gfp927z]

Royale Energy (ROYL) - interesting chart. Up 17% today while the overall market was down big. The company announced 2 more natural gas discoveries in its core area. Chart blew through the 200 MA on big volume, closing near the high of the day. Now at a key resistance level ~$4. Get through that and the next stop could be $5 and higher. The stock has a history of some big spikes -



http://stockpickr.com/7-stocks-under-10-moving-higher.html













>>> Royale Energy (ROYL) is an independent oil and natural gas producer. This stock is trading up 14% to $3.54 in recent trading.

Today’s Range: $3.07-$3.58

52-week Range: $1.73-$7.90

Volume: 381,000

Three-Month Average Volume: 250,517

From a technical standpoint, this stock is just starting to challenge its 200-day moving average of $3.53 today on above average volume. Market players should now watch for a sustained move and close above $3.53.

If we see that action today, then look to play the next major breakout on ROYL, which will trigger on a high-volume move over some near-term overhead resistance at $3.64. A high-volume move over that level will set up this stock to potentially re-test more resistance at $4 to $4.16 a share. Any high-volume move over $4.16 in the near future should be considered very bullish for this stock. <<<

[gfp927z]

American Electric Technologies - info -


http://www.thestreet.com/story/11319234/6/6-stocks-at-new-52-week-highs.html




>>> American Electric Technologies(AETI) is a provider of electrical products and services to the Gulf Coast marine and industrial markets. This stock is trading up 0.25% at $3.99 in recent trading after hitting a 52-week high of $4.00 earlier in the day.

Today's Range: $3.85-$4.00

52-week Range: $1.90-$4.00

Volume: 8,725

Three-Month Average Volume: 5,518

American Electric Technologies has a market cap of $31.22 million and an enterprise value of $34.53 million. The stock trades at a price-to-sales of 0.65 and a price-to-book of 1.38. The current short interest as a percentage of the float for American Electric Technologies is very low at just 0.2%.

From a technical standpoint, this stock is triggering a breakout today now that shares have started to move above some past overhead resistance at $3.79 on above-average volume. That said, this is another very thinly traded stock since only around 5,000 shares trade on an average day.

If the stock can manage to close over $3.79, then shares set up to trade back toward its next significant overhead resistance level near $6. This is not a name I would play, however, due to the lack of volume.

For more stocks hitting new 52-week highs today, visit the 52-Week Highs Portfolio.

-- Written by Roberto Pedone in Winderemere, Fla.
<<<

[gfp927z]

Reynolds American - info -

http://www.thestreet.com/story/11319234/4/6-stocks-at-new-52-week-highs.html




>>> Reynolds America(RAI_), through its subsidiaries, manufactures and sells cigarette and other tobacco products in the U.S. This stock is trading up 0.55% at $40.33 in recent trading after hitting a 52-week high of $40.49 earlier in the day.

Today's Range: $39.67-$40.49

52-week Range: $30.94-$40.49

Volume: 1,234,000

Three-Month Average Volume: 3,273,270

Reynolds America has a market cap of $23.56 billion and an enterprise value of $25.04 billion. This stock trades at a trailing price-to-earnings of 17.8 and a forward price-to-earnings of 13.74. Its estimated growth rate for this year is 11.6%, and for the next year it's pegged at 5.8%. The current short interest as a percentage of the float for Reynolds America is very low at just 2.0%.

From a technical standpoint, this stock is starting to break out today above some past overhead resistance at $39.94. Market players should now watch for the stock to sustain a move and close above $39.94 to signal that this stock wants to trend significantly higher. Look for a high-volume close above $39.94 that registers volume near or above its three-month average action of 3.27 million.

>>Are Stocks Headed for a Year-End Rally?

Keep mind that that shares of RAI are now trading near all-time highs, so that means just about everyone who has ever bought the stock is making money. That's bullish for any stock, since investors tend to pour money into names that are acting this strong. <<<

[gfp927z]

American Superconductor - info -


http://www.fool.com/investing/general/2011/10/12/investing-101-10-stocks-with-insider-buying-and-sh.aspx


>>> 9. American Superconductor (Nasdaq: AMSC ) : Provides wind turbine designs and electrical control systems primarily in North America, Europe, and the Asia-Pacific. Shares shorted have decreased from 9.11M to 8.66M over the last month, a change that represents about 1.22% of the company's float of 37.03M shares. Over the last six months, insiders were net buyers of 1,508,478 shares, which represents about 4.07% of the company's 37.03M share float. <<<

[gfp927z]

Pacific Sunwear - info -


http://seekingalpha.com/article/308686-4-insider-stock-picks-from-the-retail-industry?source=yahoo


>>> 1. Pacific Sunwear of California Inc. (PSUN): Operates as a retailer rooted in the action sports, fashion and music influences of the California lifestyle. Market cap of $92.13M. Net insider shares purchased over the last six months at 10.33M, which is 28.80% of the company's 35.86M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.47). The stock is a short squeeze candidate, with a short float at 14.12% (equivalent to 7.75 days of average volume). The stock has had a couple of great days, gaining 6.15% over the last week. <<<

[gfp927z]

American Superconductor - info -


http://seekingalpha.com/article/308471-5-small-stocks-with-home-run-potential?source=yahoo


>>> 5. American Superconductor (Nasdaq: AMSC)


Nov 16, 2011 -


Recent price: $4.06

This maker of wind turbines deserves a mention, albeit short (I profiled this company in more detail here). The abrupt end of a large and profitable relationship with Chinese wind-power provider Sinovel has led to a sharp drop in the company's results. But just-released quarterly results show a 30% sequential jump in bookings as the company lands new customers. A lawsuit that seeks $1 billion in damages from Sinovel could be a game changer for the company, which is valued at just $230 million. I dont' have a precise price target yet because there are too many variables right now -- where the stock goes depends on the outcome of the lawsuit with Sinovel, backlog growth and the move back to profitability. But it's definitely worth monitoring it to see if business rebounds. <<<



March 2011 -


http://www.streetauthority.com/value-investing/these-3-stocks-are-absolute-bargains-458138



>>> 1. American Superconductor (Nasdaq: AMSC)

I first profiled this maker of wind turbine equipment about a year ago, noting that the company was in the midst of a strong growth phase. Back then, I noted that sales looked set to rise to $400 million in fiscal (March) 2011. Instead, American Superconductor pre-announced sales of $435 million, up nearly 40% from the prior year. Trouble is, management said that the upcoming June quarter will see a sequential dip in sales before sales growth returns in subsequent quarters. The predictable reaction: investors dumped the shares down to a 52-week low of $21.70 on Monday, March 14.

Perhaps lost in all the action was that American Superconductor also announced an impressive $265 million acquisition that greatly expands the number of products it sells into its base of wind power customers. American Superconductor is acquiring Finland-based Switch Engineering, which provides power converter systems. Switch has been focusing on the use of large permanent magnets that capture energy from spinning turbines. These are increasingly replacing gearing systems, which have tended to wear out in these high stress environments.

In posting the deal, American Superconductor noted the things I look for: Most of the deal is being paid from existing cash balances, meaning it is not issuing too many new shares or issuing debt; the deal will immediately boost profits (on a per-share basis); and the acquired company faces a large potential market, perhaps on the order of $1 billion annually.

As noted, American Superconductor expects to see a modest sales slowdown in the June quarter. Yet, the company remains the premier play on wind power in China. The rising concerns about nuclear power due to the disaster in Japan could well encourage China to step up an already-ambitious wind power development program. With or without that, I expect American Superconductor to be a solid grower -- on an annual basis -- despite any near-term concerns. <<<

[gfp927z]

ID Systems (IDSY) -

http://www.thestreet.com/story/11307534/2/6-stocks-hitting-new-52-week-highs.html
















>>> I.D. Systems(IDSY_) develops, markets and sells wireless solutions for managing and securing enterprise assets. These assets include industrial vehicles, such as forklifts and airport ground support equipment, and rental vehicles. This stock is trading up 3% to $6.05 in recent trading, after it hit a 52-week high of $6.34 earlier today.

Today's Range: $5.85-$6.34

52-week Range: $2.51-$6.34

Volume: 79,000

Three-Month Average Volume: 40,686

I.D. Systems has a market cap of $67.26 million and an enterprise value of $46.05 million. The stock trades at a forward price-to-earnings of 120.40. Its estimated growth rate for this year is 54.5%, and for next year it's pegged at 114.3%. The current short interest as a percentage of the float for I.D. Systems is a very low 0.4%.

This stock is moving higher today after the company reported record third-quarter revenue that was up 74%.

From a technical standpoint, this stock is triggering a major breakout today now that shares have started to move above some past overhead resistance at 5.77 to $5.94 on heavy volume.

If this stock can sustain this move and close above those levels, then it should set up to trend much higher in the near-term.<<<

[gfp927z]

Applied Micro Circuits (AMCC) -

http://stockpickr.com/5-stocks-under-10-setting-soar.html?cm_ven=splinks















>>> Another under-$10 stock that’s setting up for a big breakout and potential move higher is semiconductor maker Applied Micro Circuits (AMCC). The sellers have been in control of this stock in 2011, and shares are off by over 30%. That said, the stock could quickly be changing its trend back towards the favor of the bulls if shares can break out in the near future.

If you take a look at the chart for Applied Micro Circuits, you’ll notice that this stock had been basing and trading sideways since August between $4.70 and over $6 a share. Every time this stock traded down to near $5 or just under $5, the buyers swarmed in and supported the share price. Now the buyers have started to push this stock into breakout territory since its well above $6 and pushing towards its next significant overhead resistance level at $7.16 a share.

One could be a buyer of this stock once it sustains a move and close above $7.16 a share on strong volume. Look for volume that’s tracking in close to or above its three-month average action of 1.01 million shares. Volume on Thursday (an up day) tagged 3.04 million shares, so look for this strong volume action to continue if AMCC takes out $7.16. Target a run back towards the 200-day moving average of $8.34, or potentially much higher if we get the breakout.

The current short interest as a percentage of the float for AMCC is notable at 6.5%. It’s worth pointing out that the bears have increased their bets from the last reporting period by 3.3%, or by about 133,100 shares. If the breakout triggers, then we could see the bears continue to cover some of their bets and push this stock much higher.<<<

[gfp927z]

PowerSecure (POWR) -

http://stockpickr.com/5-stocks-under-10-setting-soar.html?cm_ven=splinks














>>> If you’re looking for an under-$10 name in the energy complex, then take a look at energy services and smart grid solutions provider PowerSecure International (POWR). This stock has been off to a slow start in 2011, with shares off by over 25%. That said, the stock is soaring by over 20% today after the company reported strong third quarter results. Roth Capital also upgraded the stock today with a $6.50 price target due to those strong results and backlog.

If you take a look at the chart for PowerSecure International, you’ll notice that this stock is just starting to break out today above some past overhead resistance at $4.60 and now $5.40 a share on heavy volume. Volume today is easily going to register above its three-month average action of 138,200 shares, since at last check it’s already over 126,600 shares.

A sustained move and close above $5.40 should set this stock up for a monster run back towards the next significant overhead resistance levels at $7.50 a share, or possibly even higher.

>>5 Big Stocks to Trade for Gains

One could be a buyer of this stock off any weakness and simply use a mental stop that’s just a few percentage points below $5.40 a share. I would then simply stop out of the trade if shares move below the 50-day moving average by a few percentage points. I would add any long position once the stock takes out its 200-day moving average of $6.39 on heavy volume.

The current short interest as a percentage of the float for POWR is rather high at 9.5%. That’s a pretty high short interest, so monitor this name for continued upside in the coming days and weeks.

PowerSecure is one of TheSTreet Ratings' top-rated scientific instrument stocks.<<<

[gfp927z]

Paetec (PAET) -

http://stockpickr.com/5-stocks-under-10-setting-soar.html?cm_ven=splinks















>>> An name under-$10 name in the communications services complex that’s worth watching is Paetec (PAET). This stock has been off to a hot start this year, with shares up over 40% so far. This company just reported third-quarter earnings that showed a 31% jump in revenue growth year over year to $536.3 million. Despite those strong results, the stock is trading off by 7% at last check.

If you take a look at the chart for Paetec, you’ll notice that this stock has been in a strong uptrend for the past six months, where shares have been making mostly higher highs and higher lows. Before today’s down move, the stock was approaching a major breakout above $5.71 to $5.84 a share. That said, the stock has now dropped back below its 50-day moving average of $5.50 a share. Shares of Paetec are now approaching some key support zones at $5.25 and then near $5 a share, if that $5.25 support fails to hold.

>>5 Breakout Trades in This Crazy Market

I would suggest putting this stock on your trading radar to see if those support zones hold, or to monitor for a high volume move back above the 50-day moving average. Paetec's three-month average volume is 2.29 million shares, so any move above the 50-day with volume near or above that level is what you should watch for.

If the stock can find solid buying support near $5.25 or $5 a share, then one could be a buyer with a tight mental stop just below either entry. If you like to play strength, then I would wait until this stock makes a high volume move back above its 50-day. I would add to any long position if you see this stock break out over $5.84 with heavy volume.<<<

[gfp927z]

Majesco Entertainment (COOL) -

http://stockpickr.com/5-stocks-under-10-setting-soar.html?cm_ven=splinks















>>> Another under-$10 name that should be on your radar right now is video game maker Majesco Entertainment (COOL). This stock has been a market leader in 2011, with shares up by a whopping 330%.

If you take a look at the chart for Majesco, you’ll notice that this stock sold off hard from its June high of $4.53 to a recent low of $1.61 a share. Since hitting that low, the stock has rebound back to over $3 a share and its now nearing a major breakout. Traders should now be watching this stock for a breakout play if shares can manage to move above some past overhead resistance at $3.47 to $3.57 a share on heavy volume.

>>11 Stocks to Play the Groupon IPO

Volume on Thursday registered 2.29 million (an up day), which is well above its three-month average action of 1.31 million shares. Market players should now watch for any future breakout that shows a continuation of that high volume pattern. If we do indeed get the high volume breakout, then I think this stock can easily re-test its 52-week high of $4.53 a share.

One could be a buyer of this stock off any significant weakness and simply anticipate the breakout. I would use a mental stop just below some near-term support at $3 a share. A better way to play this is to simply buy the breakout once it takes out $3.47 to $3.57 with strong volume.

The current short interest as a percentage of the float for COOL is 5.5%. If we do see that breakout in the coming days or weeks, then look for a solid short-covering rally to materialize since the short interest is decent here.<<<

[gfp927z]

Cytori (CYTX) -

http://stockpickr.com/5-stocks-under-10-setting-soar.html?cm_ven=splinks















>>> One under-$10 stock that’s worth keeping an eye on is medical products and device maker for regenerative medicine Cytori Therapeutics (CYTX). This stock has been hammered by the sellers in 2011, with shares off by over 43%.

If you take a look at the chart for Cytori, you’ll notice that this stock has been downtrending from its July high of $5.72 to its recent low of $2.32 a share. After hitting that low, the stock has rebounded and started to print higher lows, which could be signaling a bullish trend change. As long as this stock continues to make higher lows, then traders should watch CYTX for a breakout in the near-term.

Market players should look for a breakout to trigger if CYTX can clear and close above its 50-day moving average of $3.10 a share on solid volume. Look for volume that’s tracking in close to or above its three-month average action of 432,400 shares. If the stock can close over its 50-day convincingly, then watch for a bigger breakout to trigger once it moves above $3.30 to $3.50 with volume.

One could be a buyer of this stock once it clears the 50-day with volume. If we get that move, I would then add to any long position once the stock takes out $3.30 a share with volume. Target a run back towards 4.50 a share, or possibly much higher if the bulls gain full control of this stock.

Keep in mind that this is a heavily shorted name since the current short interest as a percentage of the float for CYTX is 18%. Any near-term breakout could trigger a monster short-squeeze, so make sure to watch for any high volume spikes above that 50-day in the coming days or weeks. <<<

[gfp927z]

CytRx (CYTR) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-2










>>> One final under-$10 stock that’s worth tracking at current levels is penny stock CyRx (CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. This stock has been hammered by the bears in 2011, with shares off by over 60%.

If you take a look at the chart for CytRx, you’ll notice that this stock gapped down back in late July from over 60 cents to a low of 40.5 cents a share. After that gap down which occurred with huge volume, the stock continued to trend lower and recently hit a 52-week low of 27 cents in early October. Since that October low, the stock has started to change its trend to the upside and shares are now making higher lows and higher highs, which is bullish. Shares of CYTR are now approaching a major breakout if it can manage to move above some near-term overhead resistance levels.

Traders should watch CYTR for a breakout if it can take out 42.4 cents to 47 cents on high volume. Look for volume that’s tracking in close to or above its three-month average volume of 784,608 shares. Volume on Thursday registered 850,000, with the stock closing up 1.2%. If we see a sustained move and close above those resistance prices soon, then this stock could easily explode and attempt to refill some of that gap down from July.

Traders should look to buy this stock once it breaks out over 42.4 cents with strong volume. I would simply use a mental stop just under the 50-day moving average of 35 cents. You could also anticipate the breakout and buy off any weakness and again use that same stop near 35 cents. I would add to any long position once this stock takes out 47 cents to 50 cents with volume, since those prior resistance levels are right near the gap down day high price.

To see more hot under-$10 stocks, including Mad Catz (MCZ), Live Nation (LYV) and Dendreon (DNDN), check out the Stocks Under-$10 Setting Up To Trade Higher portfolio on Stockpickr
<<<

[gfp927z]

Oncothyreon (ONTY) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-2











>>> Another under-$10 name in the biotechnology and drugs complex that looks interesting is Oncothyreon (ONTY), which is focused primarily on the development of therapeutic products for the treatment of cancer. This stock has been on absolute fire this year with shares up by over 120%.

If you take a look at the chart for Oncothyreon, you’ll see that this stock plunged from its July high of $11.59 to a recent low of $5.67. After printing that low, the stock formed a sideways trading pattern between $5.63 and $7.75. That sideways pattern has been in place since early August, but now the stock is close to triggering a breakout trade on a move outside of the sideways pattern. On Wednesday, the stock also soared back above its 50-day moving average of $6.54 on huge volume, which is bullish.

That move was mostly due to a note from Wedbush, which boosted its price target from $15 to $31 a share ahead of the STIMUVAX phase III data set for the first quarter of 2012. What’s impressive about the stock’s performance on Thursday is that the volume continued to expand and the stock added another 5%. Volume was over 2 million on Wednesday and 1.5 million on Thursday, well above its three-month average action of 507,800 shares.

Market players should now watch for a major breakout to trigger for ONTY if it can clear some past overhead resistance at $7.54 to $7.75 on high volume. A high-volume move above those levels could easily set this stock up for a ridiculous spike higher.

This stock is heavily shorted with over 21.2% of the float currently sold short by the bears. (It shows up on an October list of the 10 Most-Shorted Stocks in Biotech.) If we do get that breakout soon, then it’s possible this stock makes a run at its 52-week high of $11.59, or possibly even higher.

You could be a buyer of this stock off any weakness and anticipate the breakout over $7.54 to $7.75 a share. I would simply use a mental stop right around the 50-day moving average of $6.54. You could also just buy off strength once the stock does trigger that breakout and simply use a much tighter mental stop near $7 a share.

Oncothyreon was also one of 13 Biotech Stocks Bought and Sold by Hedge Funds in the most recently reported quarter. <<<

[gfp927z]

Idenix (IDIX) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-2












>>> One name under-$10 name in the biotechnology and drugs complex that’s worth watching here is Idenix Pharmaceuticals (IDIX), which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the U.S. and Europe. This stock has been blazing a trail to the upside in 2011, with shares up over 40%.



If you take a look at the chart for Idenix Pharmaceuticals, you’ll notice that this stock plunged from its July high of $7.03 to a recent low of 4.06 a share. After tagging that low, the stock then ran up to $6.20 and formed a double top. Shares subsequently plunged back down to $4.30. Since hitting $4.30 in October, the stock has started to form a more bullish pattern with shares making higher highs and higher lows. The stock now sets up for a major breakout if it can sustain a move and close above some near-term overhead resistance levels.

Market players should watch for IDIX to clear $7.16 to $7.60 (Thursday’s high) on high volume. Traders should look for volume that’s tracking in close to or above its three-month average action of 646,500 shares. Volume on Thursday hit about 1.2 million shares, with the stock finishing up 2.7% to $7.18. That means the first breakout level has hit and now all this stock needs to do is close over $7.60 with solid volume.

You could be a buyer of this stock off any noticeable weakness and simply use a mental stop near Thursday’s low of $6.96. If you want to buy off strength, then buy some shares once it takes out $7.60 on high volume. A close over $7.60 should set this stock up to trend back towards its next significant resistance level at $10 a share, or possibly even higher.

Idenix, a stock in Seth Klarman's portoflio, shows up on a list of 13 Biotech Stocks Bought and Sold by Hedge Funds in the most recently reported quarter. <<<

[gfp927z]

Antares Pharmaceutical (AIS) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-2










>>> Another under-$10 name that’s already started to trigger a major breakout is Antares Pharmaceuticals (AIS), a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. Wall Street bulls seem to love this stock; shares are off to a very hot start in 2011 up over 55%.

If you take a look at the chart for Antares Pharma, you’ll see that this stock took a dive from its July high of $2.65 to a recent low of $1.80 a share. Since printing that low, the stock has rebounded nicely to its current price of $2.68. This stock has now officially triggered a breakout trade since the shares have managed to close above some past overhead resistance at $2.65 on monster volume. Volume on Thursday hit 2 million, and volume on Wednesday (an up day) was 3.34 million, both well above the three-month average action of 699,943 shares.

>>Stocks Rising on Unusual Volume

One could now be a buyer of this stock off any noticeable weakness since shares have already closed in breakout territory. I would use a mental stop just below the 50-day moving average of $2.29 if you’re looking to swing this for a longer-term trade. If you prefer to buy strength, than buy the next pullback and use a mental stop at around $2.50 to $2.40 a share.

It’s worth mentioning that this stock has a decent short interest, with 8.8% of the tradable float sold short by the bears. The short-sellers have also been increasing their bets recently by 14.4%, or by about 1 million shares Now that a high-volume breakout has triggered for AIS, we could easily be in the early innings of a massive short-squeeze.<<<

[gfp927z]

China Shen Zhou Mining (SHZ) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-2












>>> One under-$10 stock that’s starting to look interesting is China-based rare earth metals player China Shen Zhou Mining Resources (SHZ). The sellers have crushed this stock in 2011, with shares off by over 70%.

If you take a look at the chart for China Shen Zhou Mining & Resources, you’ll see that this stock has been uptrending since it hit its October low of 97 cents. During that uptrend, the stock has been making higher lows and higher highs, which is bullish price action. Market players should now monitor SHZ for a breakout trade if it can manage to clear some overhead resistance at $2.64 to $2.73 a share on high volume.

>>6 Stocks at New Highs Triggering Breakouts

The stock managed to move above $2.64 on Thursday and hit an intraday high of $2.73 a share, before pulling back and finishing the day down 4.49% to $2.34. The volume Thursday was high with 962,500 shares traded, whichh is well above the three-month average of 274,300.

This action is telling me the stock wants to pull back more in the short term but that traders should still keep an eye on those breakout levels for when the pullback is over. What’s key here is that the stock doesn’t trade back below the 50-day moving average of $1.88 on high volume off any drop. As long as the 50-day remains intact, then I still like this setup.

You could be a buyer of this stock off any high-volume move and close above $2.64 to 2.73 a share. I would simply use a mental stop a few percentage points below those breakout levels if you buy off of strength. You could also buy this name off weakness as long as $1.88 isn’t violated to the downside. I would target a spike towards $3 to $3.50 (its 200-day) a share, or even higher if a high-volume breakout triggers soon for SHZ. <<<

[gfp927z]

Cyanotech (CYAN) -

http://stockpickr.com/7-stocks-hitting-new-52-week-highs.html-0












>>> Cyanotech

Cyanotech (CYAN) is engaged in the cultivation and production of microalgae into natural health and nutrition products. This stock is trading up 6.2% to $5.35 in recent trading after hitting a 52-week high of $5.68 earlier in the day.

Today’s Range: $5.18-$5.68

52-week Range: $2.35-$5.68

Volume: 59,000

Three-Month Average Volume: 14,415

Cyanotech has a market cap of $28.88 million and an enterprise value of $24.83 million. The stock trades at a trailing price-to-earnings of 15.75. The current short interest as a percentage of the float for Cyanotech is very low at just 0.1%.

This stock is trading up today after the company reported quarterly revenue of about $6 million, compared with $3.8 million in the same quarter last year.

From a technical standpoint, this has started to challenge a big breakout above some past overhead resistance at $5.49. The next significant overhead resistance sits at $5.76.

Market players should now watch for a sustained high-volume move and close above both of those levels to signal that this stock wants to trend much higher. Look for volume that’s tracking in close to or well above 14,415. So far today, the volume is strong, so watch to see if we get a close above $5.49 to $5.76. <<<

[gfp927z]

Analysts International (ANLY) -

http://stockpickr.com/6-stocks-new-highs-triggering-breakouts.html











>>> Analysts International (ANLY) is an information technology services company. Analysts International provides a range of services designed to help businesses and government agencies. This stock is trading up 4% to $5.16 in recent trading, after it hit a 52-week high of $5.27 earlier today.

Today’s Range: $5.00-$5.27

52-week Range: $2.07-$5.27

Volume: 38,000

Three-Month Average Volume: 14,188

Analysts International has a market cap of $26.24 million and an enterprise value of $19.10 million. The stock trades at a trailing price-to-earnings of 8.86. The current short interest as a percentage of the float for this stock is very low at 0.1%.

>>Top-Rated IT Services Stocks

From a technical standpoint, this stock is triggering a big breakout today now that shares have started to move above some past overhead resistance at $4.85 to $5 on heavy volume.

Market players should watch for a sustained move and close above $5 and then $5.26 to trigger a potential move higher for this stock. The only problem is that this equity is thinly traded, with only 38,000 shares traded so far today. I prefer to trade stocks that at least register 100,000 shares on an average trading day.

That said, a move over $5.26 should mean this stock wants to trend higher in the near future. <<<

[gfp927z]

Royale Energy (ROYL) -

http://stockpickr.com/7-stocks-under-10-moving-higher.html












>>> Royale Energy (ROYL) is an independent oil and natural gas producer. This stock is trading up 14% to $3.54 in recent trading.

Today’s Range: $3.07-$3.58

52-week Range: $1.73-$7.90

Volume: 381,000

Three-Month Average Volume: 250,517

From a technical standpoint, this stock is just starting to challenge its 200-day moving average of $3.53 today on above average volume. Market players should now watch for a sustained move and close above $3.53.

>>Top-Rated Oil & Gas Stocks

If we see that action today, then look to play the next major breakout on ROYL, which will trigger on a high-volume move over some near-term overhead resistance at $3.64. A high-volume move over that level will set up this stock to potentially re-test more resistance at $4 to $4.16 a share. Any high-volume move over $4.16 in the near future should be considered very bullish for this stock. <<<

[gfp927z]

CalAmp (CAMP) -

http://stockpickr.com/7-stocks-under-10-moving-higher.html










>>> CalAmp

CalAmp (CAMP) develops and markets wireless communications solutions that deliver data, voice and video for critical networked communications and other applications. This stock is trading up 10% at $4.30 in recent trading.

Today’s Range: $3.84-$4.49

52-week Range: $2.46-$4.49

Volume: 280,000

Three-Month Average Volume: 82,762

This company is soaring higher today after CalAmp announced it was awarded a $4.7 million extension of its development contract to help design and supply initial radios for the North American interoperable Positive Train Control system.

From a technical standpoint, this stock has started to trigger a big breakout today now that it has begun a high-volume move above some past overhead resistance at $3.85 to $4 a share.

If this stock can sustain a move and close above $4, then I would look for shares of CAMP to trend significantly higher in the coming days and weeks, as long as it stays above those breakout levels. <<<

[gfp927z]

Potential Pincher Plays -
****************************


Diamond Foods (DMND) - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934550

[gfp927z]

Stockpickr article - 11-11-11 - Cisco, Pacific Sunwear, S3Bio, Ubiquiti Networks, Velti
http://stockpickr.com/5-stocks-setting-break-out.html-12


Cisco (CSCO) - breakout, could close large gap ***************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934626

Pacific Sunwear (PSUN) - ascending triangle *****************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934672

3SBio (SSRX) - ascending triangle ********************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934727

Ubiquiti Networks (UBNT) - recent IPO
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934782

Velti (VELT) - ascending triangle********************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68934814

[gfp927z]

Stockpickr article - 11-10-11 - Rite Aid, Home Depot, Broadcom, Mead Johnson, Hershey
http://stockpickr.com/5-breakout-stocks-recoup-your-losses.html


Rite Aid (RAD) - just popped
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68897096

Home Depot (HD) - *****************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68897310

Broadcom (BRCM) - if-when channel watch
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68897491

Mead Johnson (MJN) - channel bounce
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68897913

Hershey (HSY) - channel bounce
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68898164

[gfp927z]

Stockpickr article - 11-10-11 - American Superconductor, Plug Power, Pacific Ethanol, Alliance Healthcare, Medquist Holdings - http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1


American Superconductor (AMSC) -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68999473

Plug Power (PLUG) -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68999960

Pacific Ethanol (PEIX) -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69000496

Alliance Healthcare (AIQ) -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69001683

MedQuist Holdings (MEDH) -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69001995

[gfp927z]

Stockpickr article - 11-8-11 - Prudential Financial, Apache, Patriot Coal, Dunkin Brands, ATT
http://stockpickr.com/5-breakout-trades-avoid-eurozone-fallout.html


Prudential Financial (PRU) - post breakout throwback
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68943294

Apache (APA) - head + shoulder ****************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68943357

Patriot Coal (PCX) - post breakout consolidation
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68943395

Dunkin Brands (DNKN) - recent IPO, if-when channel watch
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68943443

ATT (T) - ascending triangle **************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68943485

[gfp927z]

MedQuist Holdings (MEDH) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1











>>> One more under-$10 stock that’s setting up for a big breakout and potential monster move higher clinical documentation solutions provider to the health care sector MedQuist Holdings (MEDH). This stock has traded virtually flat in 2011, with shares off by just 0.33%. That said, if a near-term technical breakout triggers, then we could see a big pop that will put flat performance in the rearview mirror.

If you take a look at the chart for MedQuist, you’ll notice that this stock was hammered from its August high of $13.77 to a recent low of $6.21 a share. After printing that low, the stock has rebounded sharply to its current price of around $9 a share. During that rebound, the stock has started to make higher lows and higher highs, which is bullish price action for any stock. The stock now sets up for a big breakout if some past overhead resistance can be taken out to the upside.

>>5 Beaten-Down Tech Stocks Poised to Rebound

Traders should monitor MEDH for a breakout if it can clear $9.08 to $9.65 a share on high volume. Look for volume that’s tracking in close to or above its three-month average action of 255,530 shares. Volume today has already surpassed 320,000 shares, and the stock is moving up over 4% to $9 a share at last check. If we do see a sustained move and close above those resistance levels soon, then this stock could easily run make a 20% to 30% pop from current levels.

One could buy this stock once it breaks out over $9.08 with strong volume. I would simply use a mental stop that’s a few percentage points below your breakout entry price. You could also anticipate the breakout and buy off any weakness back towards $8.50, with a mental stop just below that level.

The current short interest as a percentage of the float for MEDH is notable at 5.9%. That’s not a huge short interest, but it’s more than enough to spark a big short-squeeze if we do get that breakout in the coming days or weeks.

To see more hot under-$10 stocks, inclusing Power-One (PWER), Office Depot (ODP) and Aegean Marine Petroleum Network (ANW), check out the Stocks Under-$10 Setting Up To Trade Higher portfolio on Stockpickr. <<<

[gfp927z]

Alliance Healthcare (AIQ) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1











>>> If you’re looking for an under-$10 name in the health care facilities complex, then take a look at Alliance HelathCare Services (AIQ), a national provider of outpatient diagnostic imaging services and a provider of radiation oncology services. This stock has been crushed in 2011, with shares off by around 69%. That huge drop could be about to change rapidly though if the bulls are ready to take back control if this stock.

If you take a look at the chart for Alliance HealthCare Services, you’ll notice that this stock gapped down big in August from over $2.75 to a low of $1 a share. After that massive gap down in price, the stock has been trading in a sideways trading pattern between around $1.60 and $1.02 a share. The stock just started to move back above its 50-day moving average of $1.22 and it’s now setting up for a big breakout if it can manage to clear some past overhead resistance at $1.36 a share. A move over that level should set this stock up to re-test its next significant resistance level at $1.64 a share at the minimum.

>>Does Technical Trading Really Work?

One could be a buyer of this stock off any weakness and anticipate the breakout. I would simply use a mental stop that’s just a few percentage points below the 50-day moving average of $1.22 if you get long of weakness. You could also buy off strength and get long once it takes out $1.36 with high-volume.

Look for volume on any breakout that’s tracking in close to or above its three-month average action of 275,205 shares. I would then add to any long position once the stock then takes out $1.64 with high-volume. Target a run back towards $2.25 or possibly even higher if the breakout sustains a move and close over $1.64.
<<<

[gfp927z]

Pacific Ethanol (PEIX) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1











>>> A stock under-$10 name in the chemical manufacturing complex that’s worth eyeing here is Pacific Ethanol (PEIX), a marketer and producer of low-carbon renewable fuels in the Western U.S. This stock has traded virtually flat in 2011, with shares up by just 1.15%.

If you take a look at the chart for Pacific Ethanol, you’ll notice that this stock plunged from its June high of close to $2.50 a share to a recent low of 25 cents a share. After hitting that low, the stock started to trade sideways and broke out over 36 cents and then run up to its current price of 73 cents. Now the stock is setting up for a major breakout if it can manage to clear some past overhead resistance with high volume.

>>5 Breakout Stocks to Recoup Your Losses

Market players should now watch for PEIX to clear 77 cents on volume that’s close to or well above its three-month average action of 4.35 million shares. The stock has already hit 75 cents today intraday trading and volume is tracking in very strong at over 4.68 million shares at last check. If this stock does trigger a breakout in the coming days or weeks over 77 cents, then look for a monster move back towards $1.12 or possibly much higher.

Once could simply be a buyer of this stock off any near-term weakness and simply use a stop at around 70 cents a share. You could also just buy into strength and get long once 77 cents is taken out to the upside with heavy volume. Use a tight mental stop just below 77 cents if you buy off of strength. <<<

[gfp927z]

Plug Power (PLUG) -

http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1











>>> Another under-$10 name that should be on your radar right now is fuel cell systems maker Plug Power (PLUG). This stock has struggled so far in 2011, with shares off by around 38%.

If you take a look at the chart for Plug Power, you’ll see that this stock plunged from its May high of $6.20 to a recent low of $1.35 a share. After hitting that low, the stock has started to rebound and print higher highs and higher lows, which is bullish price action. The stock now sets up for a big breakout if it can manage to clear some past overhead resistance levels.

Market players should watch for a breakout trade to trigger if PLUG can manage to move above $2.36 to $2.63 on high-volume. A sustained move and close above those levels should set this stock up to re-test its 200-day moving average of $3.82, or possibly even higher. Traders should watch for volume to register close to or above its three-month average action of 200,411 shares on any breakout.

>>Stocks Rising on Unusual Volume

One could be a buyer of this stock off any significant weakness and simply anticipate the breakout. I would use a mental stop just below some near-term support at $2.12 if you buy off weakness. If you prefer to buy strength, than buy the breakout once it takes out $2.36 with strong volume. Use a tight mental stop a few percentage points below $2.36 if you get long off strength.

The current short interest as a percentage of the float for PLUG is 7.3%. If we do see that breakout in the coming days or weeks, then look for a solid short-covering rally to materialize since the short interest is decent here. <<<

[gfp927z]

American Superconductor (AMSC) -


http://stockpickr.com/5-stocks-under-10-big-upside-potential.html-1









>>> One under-$10 stock that’s worth watching here is power technology player American Superconductor (AMSC). The bears have done a number on this equity in 2011, and shares are off by over 84%.

If you take a look at the chart for American Superconductor, you’ll see that this stock has been doing nothing but trending lower since its July high of $9.15. The stock recently hit a low of $3.21 and has started to rebound to its current price of near $4.30 a share. Market players should now monitor AMSC for a breakout trade if a couple of key technical levels can be taken out to the upside in the coming days or weeks.

Those breakout levels worth watching are the 50-day moving average at $4.66 and some past overhead resistance at $4.79. Traders should watch for a high-volume move above those levels to trigger a potentially big move higher. Look for volume on the breakout that’s tracking in close to or above its three-month average action of 1.3 million shares.

>>Semiconductor Stocks Liked by Hedge Funds

This stock has failed to make a sustained move above the 50-day in months, so if that does occur soon on high volume, I would consider it a bullish development. One could be a buyer of this stock once it takes out the 50-day and $4.79 on high-volume. Simply use a stop that’s a few percentage points below the 50-day in case the breakout fails.

Keep in mind that this is a heavily shorted name since the current short interest as a percentage of the float for AMSC is 30.3%. Any near-term breakout could trigger a monster short squeeze, so make sure to watch for any high volume spikes above that 50-day in the coming days or weeks. <<<

[gfp927z]

ATT (T) -

http://stockpickr.com/5-breakout-trades-avoid-eurozone-fallout.html











>>> Last up this week is $174 billion telecom company AT&T (T), one of TheStreet Ratings' top-rated telecom stocks. AT&T has had its share prices stifled in 2011 by concerns over its troubled merger plans with T-Mobile. Now that the outcome is slightly clearer, so are AT&T’s technicals.

Like the rest of the market, AT&T bottomed at the start of August, but since then, shares have been forming an ascending triangle setup. Simply put, an ascending triangle is a formation that’s characterized by a horizontal resistance level acting as a price ceiling for AT&T at $29.50, with uptrending support below. As shares bounce in between those two technically significant price levels, they’re getting squeezed closer to a breakout above that resistance level. The breakout above $29.50 resistance is the buy signal to watch for.

14-day RSI has been providing bullish confirmation for this setup as shares make their way up to test resistance. While that adds to the likelihood of an upside breakout, the trading signal still needs to be the price breakout itself. If you take this trade, I’d recommend a protective stop just below the 200-day moving average.

To see these plays in action, check out the Technical Setups for the Week portfolio at Stockpickr. <<<